论文部分内容阅读
2型糖尿病(type 2 diabetes mellitus,T2DM)是一种由基因、环境等多种因素影响的、缓慢进展的慢性代谢性疾病,其发病的中心环节是胰岛素抵抗(insulin resistance,IR)和胰岛β细胞功能缺陷。持续性高血糖是诱发和加重胰岛β细胞功能衰竭的最主要因素,还可进一步增加IR,IR贯穿在T2DM发生发展的始终,β细胞分泌功能的缺陷则是其发病的必要条件,而β细胞功能逐渐衰竭又是DM病情逐渐进展的驱动力量。给予患者胰岛素泵联合二肽基肽酶(dipeptidyl peptidase,DPP)Ⅳ抑制剂治疗,可快速改善患者胰岛素分泌的第1时相、迅速降低糖毒性、减少胰高血糖素释放、保护及修复胰岛β细胞、增加胰岛素的敏感性、减少IR,同时兼顾不增加患者体重及保护患者心脑血管。
Type 2 diabetes mellitus (T2DM) is a slowly-evolving chronic metabolic disease that is affected by many factors such as gene and environment. The central part of T2DM is insulin resistance (IR) and islet β Cell dysfunction. Persistent hyperglycemia is the most important factor inducing and exacerbating islet β-cell failure, and further increasing IR and IR throughout the development of T2DM. The defect of β-cell secretory function is a necessary condition for its pathogenesis. However, β-cell Gradual failure of function is the driving force of gradual progress of DM. Patients given insulin pump combined with dipeptidyl peptidase (DPP) Ⅳ inhibitor treatment can rapidly improve the patient’s first phase of insulin secretion, rapidly reducing the toxicity of glucose, reducing the release of glucagon, protecting and repairing islet β Cells, increase insulin sensitivity, reduce IR, taking into account both patients do not increase body weight and protect the cardiovascular and cerebrovascular.